NSE / BSEHealthcare
β‚Ή1099.00-20.50-1.83%
P/E18.8Mkt Capβ‚Ή90.64 K CrEV/EBITDA18.4

Zydus Lifesciences Limited

P/E18.8Mkt Capβ‚Ή90.64 K CrEV/EBITDA18.4
Company Profile

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 15 Sept 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Strengths1

  • Strong 5-year net profit CAGR of 19.5%

Concerns1

  • Negative free cash flow (β‚Ή5 Cr)

Rule-based from financial data. Not advice.

Price Historyβ–² 6.01% over 1Y

Monthly Returns

Unlock Monthly Returns

Available on Pro and Institutional plans.

Sign up free

Year-to-Date ROI

Unlock Year-to-Date ROI

Available on Pro and Institutional plans.

Sign up free

Historical Volatility

Unlock Historical Volatility

Available on Pro and Institutional plans.

Sign up free

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή15.12 K Crβ–² 39.7%
EBITDA Growthβ€”
Net Profitβ‚Ή5.78 K Crβ–² 67.8%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 96.2%
Revenue CAGR 5Y11.3%
EBITDA CAGR 5Y17.6%
Net Profit CAGR 5Y19.5%
NP Growth 1Y67.8%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή15.12 K Crβ€”β‚Ή5.78 K Crβ€”β€”27.3%39.7%67.8%
Mar 2024β‚Ή10.82 K Crβ€”β‚Ή3.44 K Crβ€”β€”21.9%23.9%125.1%
Mar 2023β‚Ή8.73 K Crβ€”β‚Ή1.53 K Crβ€”β€”11.2%11.4%78.2%
Mar 2022β‚Ή7.84 K Crβ€”β‚Ή858.00 Crβ€”β€”6.5%0.7%-41.9%
Mar 2021β‚Ή7.78 K Crβ€”β‚Ή1.48 K Crβ€”β€”11.6%22.6%4.5%
Mar 2020β‚Ή6.35 K Crβ€”β‚Ή1.41 K Crβ€”β€”12.5%5.1%-4.9%
Mar 2019β‚Ή6.04 K Crβ€”β‚Ή1.49 K Crβ€”β€”17.3%3.9%36.2%
Mar 2018β‚Ή5.81 K Crβ€”β‚Ή1.09 K Crβ€”β€”14.1%79.8%64.8%
Mar 2017β‚Ή3.23 K Crβ€”β‚Ή662.00 Crβ€”β€”10.0%-54.1%-67.5%
Mar 2016β‚Ή7.03 K Crβ€”β‚Ή2.04 K Crβ€”β€”32.5%33.1%60.3%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Free plan Β· showing 1 year of data.Upgrade

Consolidated Figures in USD Millions.

Unnamed: 0TTM
Revenue / Net Sales13,795
Total Expenses7,636
EBIT / Operating Profit6,158
OPM %45%
Other Income962
Finance Costs504
Depreciation & Amortisation526
Profit Before Tax6,090
Tax %-
Net Profit / PAT4,826
EPS (β‚Ή)47.95
Dividend Payout %-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Zydus Lifesciences Limitedthis co.β‚Ή90.64 K Crβ‚Ή15.12 K Cr18.804.1918.3939.7%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Zydus Lifesciences Limited and the metrics that matter.

Browse the full Equiscale Academy